Distinguished in Non-Small Cell Lung Cancer (NSCLC)

Dr. Nitin Ohri

Radiology | Radiation Oncology
Montefiore Medical Center
111 E 210th St, 
Bronx, NY 
Clinical Trials:Currently Recruiting for 5 Trials
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Montefiore Medical Center
111 E 210th St, 
Bronx, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nitin Ohri is a Radiologist and a Radiation Oncologist in Bronx, New York. Dr. Ohri is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Nasopharyngeal Carcinoma, and Prostatectomy.

His clinical research consists of co-authoring 114 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 31 articles and participated in 7 clinical trials in the study of Non-Small Cell Lung Cancer (NSCLC).

Specialties
Radiology
Radiation Oncology
Licenses
Therapeutic Radiology in PA
Hospital Affiliations
Montefiore Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

MONTEFIORE MEDICAL CENTER
111 E 210th St, Bronx, NY 10467

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2/Phase 3
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases From Small Cell Lung Cancer
Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases From Small Cell Lung Cancer
Enrollment Status: Recruiting
Publish Date: September 11, 2025
Intervention Type: Procedure, Other, Radiation, Drug
Study Drug: Memantine Hydrochloride
Study Phase: Phase 3
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Enrollment Status: Recruiting
Publish Date: May 25, 2025
Intervention Type: Procedure, Radiation
Study Phase: Phase 3
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: October 10, 2025
Intervention Type: Radiation, Drug
Study Drug: Sorafenib Tosylate
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Radiation, Drug
Study Drug: FLT3 Ligand Therapy (CDX-301)
Study Phase: Phase 2
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Randomized Trial Comparing Two Radiotherapy Schedules
Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Randomized Trial Comparing Two Radiotherapy Schedules
Enrollment Status: Completed
Publish Date: June 07, 2024
Intervention Type: Combination product
Study Drugs: PET-based, dose-painted, accelerated chemoradiotherapy, Standard chemoradiotherapy
Study Phase: Phase 2
FLT3 Ligand (CDX-301), CD40 Agonist Antibody (CDX-1140), and Stereotactic Radiotherapy Versus Standard Therapy for Advanced Non-small Cell Lung Cancer: A Phase I/II Randomized Trial
FLT3 Ligand (CDX-301), CD40 Agonist Antibody (CDX-1140), and Stereotactic Radiotherapy Versus Standard Therapy for Advanced Non-small Cell Lung Cancer: A Phase I/II Randomized Trial
Enrollment Status: Terminated
Publish Date: February 28, 2024
Intervention Type: Drug, Biological, Radiation
Study Drugs: FLT3 Ligand, Anti-CD40 antibody
Study Phase: Phase 1/Phase 2
PET-Adjusted IMRT for NSCLC Trial (PAINT)
PET-Adjusted IMRT for NSCLC Trial (PAINT)
Enrollment Status: Completed
Publish Date: January 25, 2024
Intervention Type: Procedure, Drug, Radiation
Study Phase: Phase 2
A Prospective, Randomized, Phase 3 Trial of Carbon Ion Radiation Therapy Versus Standard Care for Locally Advanced Pancreatic Cancer
A Prospective, Randomized, Phase 3 Trial of Carbon Ion Radiation Therapy Versus Standard Care for Locally Advanced Pancreatic Cancer
Enrollment Status: Terminated
Publish Date: January 05, 2024
Intervention Type: Radiation, Drug
Study Drug: Chemotherapy drug
Study Phase: Phase 3
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Enrollment Status: Completed
Publish Date: May 25, 2022
Intervention Type: Radiation
Study Phase: Phase 1
A Phase I Study of Low Dose Radiotherapy for Advanced Hidradenitis Suppurativa
A Phase I Study of Low Dose Radiotherapy for Advanced Hidradenitis Suppurativa
Enrollment Status: Terminated
Publish Date: November 01, 2021
Intervention Type: Radiation
Study Phase: Not Applicable
Real-time Activity Monitoring to Prevent Admissions During RadioTherapy
Real-time Activity Monitoring to Prevent Admissions During RadioTherapy
Enrollment Status: Completed
Publish Date: May 29, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 13 Less Clinical Trials

114 Total Publications

Chemotherapy-Free Treatment with Radiotherapy and Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer.
Chemotherapy-Free Treatment with Radiotherapy and Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer.
Journal: Cancers
Published: March 26, 2025
Similar Doctors
Andreas Rimner
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Andreas Rimner
Radiation Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Andreas Rimner
Radiation Oncology
1275 York Ave, 
New York, NY 
 (9.0 miles away)
212-639-6829
Languages Spoken:
English

Andreas Rimner is a Radiation Oncologist in New York, New York. Dr. Rimner is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Mesothelioma, Non-Small Cell Lung Cancer (NSCLC), Tissue Biopsy, and Thymectomy.

Daniel R. Gomez
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Daniel R. Gomez
Radiation Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Daniel R. Gomez
Radiation Oncology

Msk Bergen

225 Summit Ave, 
Montvale, NJ 
 (15.8 miles away)
908-542-3336
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Gomez is a Radiation Oncologist in Montvale, New Jersey. Dr. Gomez is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Mesothelioma.

Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Narek Shaverdian
Radiation Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Narek Shaverdian
Radiation Oncology

Msk Monmouth

480 Red Hill Rd, 
Middletown, NJ 
 (37.9 miles away)
908-542-3007
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Narek Shaverdian is a Radiation Oncologist in Middletown, New Jersey. Dr. Shaverdian is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Gastrostomy. Dr. Shaverdian is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ohri's expertise for a condition
ConditionClose
View All 46 Advanced Conditions
View All 52 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile